The purpose of this application is to request supplementary funds to complete ongoing commitments to the Pelvic Floor Disorders Network (PFDN) at the University of Pittsburgh in 2021-2022. Our site has a longstanding track record of successful contribution to multicenter studies of urinary and fecal incontinence, and pelvic organ prolapse. The University of Pittsburgh is particularly well suited to be a clinical site in the PFDN because of our volume, research infrastructure and track record, basic and translational experience and expertise. Magee-Womens Hospital (MWH) is the hub of the Women’s Health Service Line for the 40 hospital University of Pittsburgh Health System, serving a very large aging population of women. Our site brings to the PFDN expertise in urogynecology, physical therapy, urology, gastroenterology, geriatrics, and biomechanical engineering. We offer the PFDN unique technical expertise in development of finite element models of the vagina and its supportive tissues after surgery, biochemical and biomechanical impact of meshes on the vagina, dynamic 3D MRI and transperineal ultrasound of the pelvic floor, and tissue regenerative techniques. This expertise is key to completion of the aims of the 2 ongoing translational projects of the PFDN: Defining Mechanisms of Anterior Vaginal Descent (DEMAND) trial, and the Biofabrication of vaginal support using vaginally derived cells: a Feasibility study (BioLIFT). In this application for supplementary funds to UGHD069006 we described our plan for completion of the aforementioned translational projects, and our research personnel staffing and management plan for recruitment and retention into the Mixed Urinary Incontinence: Mid-urethral Sling vs. Botox A (MUSA) trial (NCT04171531), SUPeR (NCT01802281) and ASPIRe (NCT02676973) clinical trials.